Candel Therapeutics, Inc.

Candel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing immunotherapies for cancer patients. Its lead product candidate is CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer and non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, currently in Phase Ib clinical trials for recurrent high-grade glioma. Additionally, Candel has developed the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus-based discovery platform that leverages human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. before rebranding in November 2020.

Candel Therapeutics, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol CADL. The company's stock trades in United States Dollars (USD). As a Nasdaq-listed company, it is subject to the reporting and regulatory requirements of the U.S. Securities and Exchange Commission (SEC). Investors can trade CADL shares through most brokerage platforms that offer access to U.S. stock exchanges.

Candel Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on developing innovative therapies using biological processes and living organisms. In particular, Candel specializes in viral immunotherapies for cancer, utilizing herpes simplex virus-based platforms to create treatments that stimulate the immune system to fight tumors. The biotechnology industry is characterized by high research and development costs, lengthy clinical trial processes, and significant regulatory oversight.

Candel Therapeutics is headquartered in Needham, Massachusetts, United States. The company was incorporated in 2003 and was originally known as Advantagene, Inc. before rebranding to Candel Therapeutics in November 2020. The name change reflects its strategic focus on developing immunotherapies for cancer. As a clinical stage biopharmaceutical company, it has not yet commercialized any products and continues to advance its pipeline through clinical trials. The company's location in the Boston area places it within a major biotechnology hub, providing access to talent and research resources.

Candel Therapeutics' pipeline includes two main product candidates. CAN-2409 is being developed for prostate cancer and non-small cell lung cancer (NSCLC), both in Phase 2a clinical trials. CAN-3110 is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma, an aggressive brain cancer. Additionally, the company has developed the enLIGHTEN Discovery Platform, which is a systematic, iterative herpes simplex virus-based discovery platform. This platform uses human biology and advanced analytics to generate new viral immunotherapy candidates for solid tumors. The platform represents a key part of Candel's business model, as it enables the creation of a pipeline of novel therapies beyond the current candidates.